Shire Pharmaceuticals will pay $56.5 million to settle False Claims Act cases alleging the company illegally marketed and promoted several drugs, including Adderall XR, Vyvanse, and Daytrana, which are approved for attention deficit hyperactivity disorder (ADHD), and Pentasa and Lialda, which are approved for the treatment of active ulcerative colitis.

FCA | Shire Pharmaceuticals, Joyce Branda, Patrick Burns, Eric Holder, inversion